TY - BOOK ID - 133897776 TI - Advance in the Treatment of Pediatric Leukemia PY - 2022 PB - Basel MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - Chemistry KW - acute lymphoblastic leukemia KW - pediatric KW - advances KW - diagnosis KW - treatment KW - immunotherapy KW - bispecific T-cell engager (BiTE) KW - BCP-ALL KW - leukemia KW - TRAIL KW - antibody KW - Fc-engineering KW - xenograft KW - CD19 KW - juvenile myelomonocytic leukemia KW - RAS signaling KW - hematopoietic stem cell transplantation KW - 5-azacitidine KW - myelodysplastic/myeloproliferative disorders KW - targeted therapy KW - ADC KW - antibody–drug conjugate KW - pediatric leukemia KW - ALL KW - AML KW - allogeneic stem cell transplantation KW - acute myeloid leukemia KW - minimal residual disease KW - conditioning regimen KW - alternative donors KW - B-ALL KW - DUX4 KW - IKZF1 KW - PAX5 KW - Ph-like KW - ZNF384 KW - NUTM1 KW - T-ALL KW - NOTCH1 KW - BCL11B KW - transcriptome KW - genome KW - chronic myeloid leukemia KW - CML KW - tyrosine kinase inhibitor KW - immunizations KW - COVID-19 KW - childhood acute lymphoblastic leukemia KW - low-risk ALL KW - risk-stratified treatment KW - treatment related toxicity KW - L-asparaginase KW - acute pancreatitis KW - polymorphism KW - SNV KW - ABCC4 KW - CFTR KW - other extramedullary relapse KW - lymphoblastic leukemia KW - children KW - prognosis KW - evolution of CAR T cells KW - FDA-approved CAR products KW - TcR versus CAR KW - limitations and complications of CAR T cell therapy KW - future directions of CAR T cell therapy KW - n/a KW - antibody-drug conjugate UR - https://www.unicat.be/uniCat?func=search&query=sysid:133897776 AB - The book gives an overview on the progress that has been made in the treatment of acute lymphoblastic leukemia (ALL), of acute and chronic myeloid leukemia (AML, CML) and of juvenile myelomonocytic leukemia (JMML). Leukemia is the most common malignant disease in children, and 80% of patients are diagnosed with ALL and 15–20% with AML, whereas CML and JMML are rather rare. Although ALL was considered an incurable disease until the early 1960s, with the availability of cytotoxic drugs and the start of clinical multicenter studies, ALL has become an almost curable disease with a survival rate exceeding 90 % in high-income countries. These impressive results have mainly been achieved by a deeper understanding of the genomic landscape of the disease and the introduction of risk stratifications based on genetic features and response to chemotherapy as determined by the presence or absence of minimal residual disease (MRD). Immunotherapies including bispecific T-cell Engagers (BiTEs), Chimeric Antigen Receptor (CAR) T cells, monoclonal antibodies and improvements in the outcome of allogeneic stem cell transplantation (HSCT) have shown impressive results in chemorefractory or relapsed patients, and it is anticipated that the cure rate can be further increased. For countries with less resources, therapies have to be adapted to increase survival as well. This book also updates on the progress made in the treatment of AML. As in ALL, risk classification based on genetic factors and response to chemotherapy is most important for therapy guidance. The book also provides updates and guidance for the treatment of CML and JMML. ER -